Research
312 results
Name Type Target Compound Name Phase
First Affiliated Hospital of Wenzhou Medical University

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia

New Therapies (Small Molecule) Tumor necrosis factor (TNF) alpha Thalidomide Phase II
Vasomune

AV-001 is an investigational medicine designed to activate the Tie2 receptor and restore normal barrier defense in the vasculature

New Therapies (Cell-based) Tyrosine kinase receptor 2 (Tie2) AV-001 Pre-Clinical
Colorado State University

Screening compounds against COVID-19 in BSL-3 lab

Research (Drug Repurposing) Undisclosed Unnamed Pre-Clinical
Johns Hopkins University

Clinical trial of convalescent plasma to treat COVID-19

New Therapies (Antibody-based) Undisclosed Unnamed Phase II
Emergent Biosolutions

Development of human- and horse-derived antibodies to prevent or treat COVID-19

New Therapies (Antibody-based) Undisclosed COVID-EIG Pre-Clinical
Washington University in St. Louis

Wash U Scientists Are Developing A Coronavirus Vaccine

Vaccine (Nucleic Acid-based) Undisclosed Unnamed Pre-Clinical
University of Pennsylvannia

Mechanims of antiviral compound activity against SARS-CoV-2 and other human coronavirus

Research (Drug Repurposing) Undisclosed Unnamed Pre-Clinical
University of Pennsylvannia

RNA-Based Vaccine Development

Vaccine (Nucleic Acid-based) Undisclosed Unnamed Pre-Clinical
University of Pennsylvannia

Development of non-invasive “breathalyzer” diagnostic for COVID-19

Research (Devices) Undisclosed Unnamed Pre-Clinical
Collaboration: Baylor College of Medicine, ElevateBio LLC, & AlloVir

Development of Virus-Specific Allogeneic T-cell therapies

New Therapies (Cell-based) Undisclosed Unnamed Pre-Clinical
Southwest Research Institute

Virtual Screening Tool to evalute potential activity of 2 million compounds on SARS-CoV-2

Research (Drug Repurposing) Undisclosed Unnamed Pre-Clinical
Collaboration: Arcturus Therapeutics and Duke NUS

Development of LUNAR-COV19, an mRNA-based vaccine

Vaccine (Nucleic Acid-based) Undisclosed LUNAR-COV19 Pre-Clinical
Inovio Pharmaceuticals

Development of a DNA-Based Covid-19 Vaccine currently in Phase 1 clinical trials

Vaccine (Nucleic Acid-based) Undisclosed INO-4800 Phase I
Celularity

Potential stem cell treatment for Covid-19

New Therapies (Cell-based) Undisclosed CYNK-001 IND
Collaboration: Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)

Evaluation of a 500 antibody panel for binding to SARS-CoV-2

New Therapies (Antibody-based) Undisclosed Unnamed Pre-Clinical
Kamada

Novel treatment using plasma from Covid-19 patients

New Therapies (Antibody-based) Undisclosed Anti- COVID-19 polyclonal immunoglobulin Pre-Clinical
Entos Pharmaceuticals

Development of a DNA vaccine to prevent COVID-19 infections

Vaccine (Nucleic Acid-based) Undisclosed COVID-19 DNA vaccine Pre-Clinical
Collaboration: Altimmune & University of Alabama

Development of an intranasal covid-19 vaccine

Vaccine (Viral Vector) Undisclosed AdCOVID Pre-Clinical
OyaGen

Developmemt of a compound with broad anti-coronavirus activity

Research (Drug Repurposing) Undisclosed OYA1 Pre-Clinical
BeyondSpring

An orally administered small molecule is a potent T-cell co-stimulator.

Research (Drug Repurposing) Undisclosed BPI-002 Pre-Clinical
Collaboration: Clover Biopharmaceuticals & GSK & Dynavax

Trimeric subunit Spike Protein vaccine candidate, currently in preclinical testing

Vaccine (Protein Subunit) Undisclosed Unnamed Pre-Clinical
Collaboration: Vaxart & Emergent Bioscience

Orally administered Non-replicating Viral Vector

Vaccine (Viral Vector) Undisclosed Unnamed Pre-Clinical
Enanta Pharmaceuticals

Screening new drugs identified from a library of antiviral compounds

Research (Modeling) Undisclosed Unnamed Pre-Clinical
Collaboration: CEL-SCI & University of Georgia Center for Vaccines and Immunology

LEAPS peptides improve survival in mice with respiratory virus, influenza (H1N1)

New Therapies (Protein-based) Undisclosed Unnamed Pre-Clinical
Collaboration: Heat Biologics & The University of Miami

The vaccine is designed to induce a multi-epitope specific memory CD8 T-cell response that protects against multiple, distinct coronavirus strains, and against potential future mutations of SARS-CoV-2 and other coronaviruses.

Vaccine (Protein Subunit) Undisclosed Unnamed Pre-Clinical